CASE REPORT
Published on 09 Jul 2024
Treatment of rosacea with upadacitinib and abrocitinib: case report and review of evidence for Janus kinase inhibition in rosacea
doi 10.3389/fimmu.2024.1416004
- 1,879 views
- 1 citation
- Frontiers in Immunology
- Inflammation
- Research Topics
- Community Series in JAK Inhibition in Autoimmune and Inflammatory Diseases: Volume II
Community Series in JAK Inhibition in Autoimmune and Inflammatory Diseases: Volume II
7,885
Total downloads
23k
Total views and downloads
Submit your idea
You will be redirected to our submission process.
Articles
CASE REPORT
Published on 02 Jul 2024
A novel approach with tofacitinib for the management of keratoderma blennorrhagicum in reactive arthritis: a case report
doi 10.3389/fimmu.2024.1399249
- 1,089 views
SYSTEMATIC REVIEW
Published on 21 Mar 2024
Therapeutic efficacy and safety of JAK inhibitors in treating polymyositis/dermatomyositis: a single-arm systemic meta-analysis
doi 10.3389/fimmu.2024.1382728
- 3,257 views
- 2 citations
SYSTEMATIC REVIEW
Published on 23 Feb 2024
Janus kinase inhibitors in atopic dermatitis: an umbrella review of meta-analyses
doi 10.3389/fimmu.2024.1342810
- 3,262 views
- 1 citation
REVIEW
Published on 26 Oct 2023
SOCS-JAK-STAT inhibitors and SOCS mimetics as treatment options for autoimmune uveitis, psoriasis, lupus, and autoimmune encephalitis
doi 10.3389/fimmu.2023.1271102
- 4,566 views
- 8 citations
ORIGINAL RESEARCH
Published on 31 Aug 2023
The impact of EMA recommendations on the real-life use of Janus kinases inhibitors for rheumatoid arthritis: the Expanded Risk Score in RA as a tool to quantify the risk of cardiovascular events
doi 10.3389/fimmu.2023.1225160
- 2,060 views
- 3 citations
CASE REPORT
Published on 05 Jun 2023
Case Report: Morbihan disease treated with tofacitinib successfully
doi 10.3389/fimmu.2023.1177316
- 3,015 views
- 4 citations
Published in
Frontiers in Immunology
- Inflammation
Impact
- 23kTopic views
- 14kArticle views
- 7,885Article downloads